10/8/2009 5:49 AM EST
Axcentua Pharmaceuticals AB closed its series-A financing round led by the entrepreneur William Gunnarsson, the former CEO and co-founder of Orphan Europe that now is part of the Recordati Group (Ticker REC). The financing will enable Axcentua to advance its multi-targeted lead small molecule AXP107-11 into clinical trials. The compound is intended for use as a combination therapy of different difficult-to-treat...